Edward Unkart

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

AlterG, Inc. develops weight reduction athletic equipment. Its products are used by major medical centers, leading physical therapy clinics and professional, collegiate, and individual sports and fitness programs. The firm?s products include anti gravity treadmill, bionic leg and accessories. AlterG was founded by Michael Brenton Looney, Fritz Moore, Edward Liou and Sean Whalen in 2005 and is headquartered in Fremont, CA.

VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA.